Total Valuation
NervGen Pharma has a market cap or net worth of €199.47M. The enterprise value is €129.26.
Market Cap€199.47M
Enterprise Value€129.26
Share Statistics
NervGen Pharma has 107,522,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding107,522,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NervGen Pharma’s return on equity (ROE) is -12.69 and return on invested capital (ROIC) is -719.57%.
Return on Equity (ROE)-12.69
Return on Assets (ROA)-1.90
Return on Invested Capital (ROIC)-719.57%
Return on Capital Employed (ROCE)-7.21
Revenue Per Employee0.00
Profits Per Employee-4.01M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NervGen Pharma is ―. NervGen Pharma’s PEG ratio is -0.18.
PE Ratio―
PS Ratio0.00
PB Ratio159.85
Price to Fair Value159.85
Price to FCF-28.50
Price to Operating Cash Flow-19.32
PEG Ratio-0.18
Income Statement
In the last 12 months, NervGen Pharma had revenue of 0.00 and earned -44.12M in profits. Earnings per share was -0.61.
Revenue0.00
Gross Profit0.00
Operating Income-25.08M
Pretax Income-44.12M
Net Income-44.12M
EBITDA-5.65M
Earnings Per Share (EPS)-0.61
Cash Flow
In the last 12 months, operating cash flow was -29.60M and capital expenditures 4.00, giving a free cash flow of -29.60M billion.
Operating Cash Flow-29.60M
Free Cash Flow-29.60M
Free Cash Flow per Share-0.28
Dividends & Yields
NervGen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-11.93%
50-Day Moving Average1.61
200-Day Moving Average2.77
Relative Strength Index (RSI)57.12
Average Volume (3m)926.00
Important Dates
NervGen Pharma upcoming earnings date is Nov 12, 2026, After Close (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 12, 2026
Ex-Dividend Date―
Financial Position
NervGen Pharma as a current ratio of 1.16, with Debt / Equity ratio of 0.24%
Current Ratio1.16
Quick Ratio1.16
Debt to Market Cap0.00
Net Debt to EBITDA3.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NervGen Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NervGen Pharma EV to EBITDA ratio is -94.43, with an EV/FCF ratio of -27.37.
EV to Sales0.00
EV to EBITDA-94.43
EV to Free Cash Flow-27.37
EV to Operating Cash Flow-27.37
Balance Sheet
NervGen Pharma has €86.93M in cash and marketable securities with €0.00 in debt, giving a net cash position of €86.93M billion.
Cash & Marketable Securities€86.93M
Total Debt€0.00
Net Cash€86.93M
Net Cash Per Share€0.81
Tangible Book Value Per Share€0.04
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NervGen Pharma is €10.79, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€10.79
Price Target Upside502.70% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-84.60%